Global Diagnostic Nuclear Drug Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Diagnostic Nuclear Drug Market Research Report 2024
Nuclear Drugs are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis
According to Mr Accuracy reports new survey, global Diagnostic Nuclear Drug market is projected to reach US$ 7534.8 million in 2029, increasing from US$ 4722 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Diagnostic Nuclear Drug market research.
The diagnostic radioisotopes market is driven by the increasing prevalence of cancer and cardiovascular diseases, which require advanced imaging techniques for accurate diagnosis and treatment planning. Diagnostic radioisotopes are radioactive compounds used in nuclear medicine imaging to visualize and evaluate physiological processes and detect specific diseases in the body. The rise in the aging population and the need for early and precise diagnosis contribute to market growth. Moreover, advancements in radiopharmaceutical research and the development of new radioisotopes have improved the sensitivity and specificity of diagnostic imaging. However, the market also faces challenges, including the high cost of production and limited availability of some radioisotopes. Additionally, ensuring regulatory compliance and addressing concerns regarding radiation safety can pose obstacles for manufacturers and healthcare facilities. To succeed, companies must focus on research and development to offer innovative and diverse diagnostic radioisotopes, collaborate with healthcare providers to improve nuclear medicine imaging capabilities, and address the challenges to meet the increasing demand for effective and safe diagnostic imaging solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diagnostic Nuclear Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Cardinal Health
GE Healthcare
Curium Pharma
Jubilant Pharma
Bracco Imaging
Novartis
SIEMENS
China Isotope & Radiation
Dongcheng
Lantheus
Eli Lilly
Segment by Type
Tc-99m
F-18
Other
Oncology
Cardiology
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Diagnostic Nuclear Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Diagnostic Nuclear Drug market is projected to reach US$ 7534.8 million in 2029, increasing from US$ 4722 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Diagnostic Nuclear Drug market research.
The diagnostic radioisotopes market is driven by the increasing prevalence of cancer and cardiovascular diseases, which require advanced imaging techniques for accurate diagnosis and treatment planning. Diagnostic radioisotopes are radioactive compounds used in nuclear medicine imaging to visualize and evaluate physiological processes and detect specific diseases in the body. The rise in the aging population and the need for early and precise diagnosis contribute to market growth. Moreover, advancements in radiopharmaceutical research and the development of new radioisotopes have improved the sensitivity and specificity of diagnostic imaging. However, the market also faces challenges, including the high cost of production and limited availability of some radioisotopes. Additionally, ensuring regulatory compliance and addressing concerns regarding radiation safety can pose obstacles for manufacturers and healthcare facilities. To succeed, companies must focus on research and development to offer innovative and diverse diagnostic radioisotopes, collaborate with healthcare providers to improve nuclear medicine imaging capabilities, and address the challenges to meet the increasing demand for effective and safe diagnostic imaging solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diagnostic Nuclear Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Cardinal Health
GE Healthcare
Curium Pharma
Jubilant Pharma
Bracco Imaging
Novartis
SIEMENS
China Isotope & Radiation
Dongcheng
Lantheus
Eli Lilly
Segment by Type
Tc-99m
F-18
Other
Segment by Application
Oncology
Cardiology
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Diagnostic Nuclear Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source